This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising.
SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its placement in a BioMedWire editorial examining the evolution of GLP-1 therapies and emerging innovation in obesity and metabolic disease treatment. The editorial highlights SureNano’s subsidiary GlucaPharm Inc. and its GEP-44 program, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in the rapidly expanding GLP-1 market, as demand continues to grow for next-generation therapies targeting obesity, type 2 diabetes and related chronic conditions.
To view the full press release, visit https://ibn.fm/AGdi9
About SureNano Science Ltd.
SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets with the potential to address large and growing global health markets. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery (refer to press release dated February 23, 2026). The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.
NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
